AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03680300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition.
Study NCT03680300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
Study NCT03680300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Friction Massage
Description: Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
Study NCT00723060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
Study NCT01988844 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
Study NCT00052013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Study NCT01243047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Erlotinib, Oxaliplatin, Capecitabine
Study NCT00851721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Description: 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
Study NCT00851721 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Description: FEIBA NF dose and dosing interval as prescribed by the treating physician
Study NCT01791088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT01791088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01791088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01618929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
Study NCT04359147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine + Hydrocortisone
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study NCT04359147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study NCT00801502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oily fish consumption
Description: Two portions of salmon per week from week 20 of pregnancy until giving birth
Study NCT00801502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No change to habitual diet from week 20 of pregnancy until giving birth
Study NCT03851029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints
Study NCT03851029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints
Study NCT01988129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep disorders education and screening
Description: Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
Study NCT00714194 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Normal continuous sedation
Description: Normal continuous sedation.
Study NCT00714194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily interruption of continuous sedation
Description: Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
Study NCT01396512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis chimeric virus vaccine
Description: 0.5 mL, Subcutaneous
Study NCT01396512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
Description: 0.5 mL, Subcutaneous
Study NCT03394469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: collection
Description: Blood, urinary and faecal samples
Study NCT03657186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProbioSatys™
Description: One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
Study NCT04306081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
Study NCT04364399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mumps vaccine
Description: One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
Study NCT02703480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: d-PTFE
Description: high-density polytetrafluoroethylene (d-PTFE) membrane
Study NCT02703480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ti-mesh
Description: Titanium mesh
Study NCT02516592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 micrograms
Description: QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
Study NCT02516592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 microgrammes
Description: Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
Study NCT01227941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827 + pegylated liposomal doxorubicin
Description: MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
Study NCT03720912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Learning Modules
Description: The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
Study NCT03500146 — intervention group
Intervention type: DRUG
Intervention: Anticholinergic
Description: Patients prescribed medication for OAB
Study NCT03500146 — intervention group
Intervention type: PROCEDURE
Intervention: PTNS
Description: Patients prescribed PTNS for OAB
Study NCT02999256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Juice
Study NCT02999256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02823275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional mobilisation
Description: functional mobilisation
Study NCT02823275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short term plaster cast fixation
Description: 2 weeks cast immobilisation
Study NCT02812316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens
Description: Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
Study NCT00909779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol
Description: Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
Study NCT00909779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution, twice daily (BID) for a duration of one year.
Study NCT00963261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-oncological intervention
Description: stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
Study NCT04364399 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: measles, mumps and rubella combined vaccine, live
Description: One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
Study NCT04264910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm App
Description: Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
Study NCT04912934 — intervention group
Intervention type: PROCEDURE
Intervention: A survey form was applied to individuals included in the study face-to-face.
Description: This study was completed with a descriptive, cross-sectional and relational screening model
Study NCT01743287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imotun capsule
Description: Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
Study NCT01743287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imotun capsule placebo
Description: Imotun capsule placebo: per oral, a capsule a day during 24 weeks
Study NCT01557296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary treatment: food of small particle size
Description: Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
Study NCT01557296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment: food of small particle size
Description: Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
Study NCT01557296 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Validate X-ray diagnostic method.
Description: Follow 20 radiopaque markers throw the ventricle by X-ray.
Study NCT01557296 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Validate X-ray diagnostic method.
Description: Follow 20 radiopaque markers throw the ventricle by X-ray.
Study NCT01557296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Can the motility be improved
Description: Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
Study NCT01557296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Can the motility be improved
Description: Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
Study NCT01557296 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: postprandial plasma glucose
Description: Measure the blood glucose response and gastrointestinal symptoms after a test meal
Study NCT01557296 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: postprandial plasma glucose
Description: Measure the blood glucose response and gastrointestinal symptoms after a test meal
Study NCT05128851 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: HTO
Description: Hight Tibial Osteotomy
Study NCT05128851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO
Description: Hight Tibial Osteotomy
Study NCT02904148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder mobilisation
Description: early shoulder mobilisation
Study NCT00655824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: 1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
Study NCT03742882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAP
Description: During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPT
Description: Cognitive Therapy for PTSD
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPT
Description: Cognitive Therapy for PTSD
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERRT
Description: ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERRT
Description: ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
Study NCT03657186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
Study NCT00659243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBSSL
Description: 0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
Study NCT00659243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One week treatment
Study NCT03672474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation REGEnLIFE RGn530 device
Description: For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
Study NCT03672474 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM REGEnLIFE RGn530 device
Description: For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
Study NCT03854552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: capsule
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
Study NCT05120674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
Study NCT01079936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
Study NCT01079936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
Study NCT01079936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cell infusion on Day 0.
Study NCT00783146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine, 5 mg oral tablets, once daily for 15 days
Study NCT00783146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine
Description: fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
Study NCT00783146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily for 15 days
Study NCT03854552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study NCT02211872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536 BS, intravenous
Study NCT00508144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: 500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks
Study NCT03226600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrACELL
Description: OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
Study NCT03226600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft
Description: A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
Study NCT02142569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: Sugar Pills/Placebo 4 capsules/day for 12 weeks.
Study NCT02142569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar Pills/Placebo 4 capsules/day for 12 weeks.
Study NCT04046978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConM SOSIP 50 ug and ConS UFO 50 ug
Description: Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
Study NCT05128851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy treatment
Description: Arthroscopy treatment
Study NCT05128851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro fractures
Description: Micro fractures
Study NCT04046978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mos3.1 100 ug
Description: Intramuscular injection of synthetic viral immunogen Mos3.1
Study NCT04046978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mos3.2 100 ug
Description: Intramuscular injection of synthetic viral immunogen Mos3.2
Study NCT02142569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese Red Yeast Rice (CRYR)
Description: CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
Study NCT04046978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mos3.3 100 ug
Description: Intramuscular injection of synthetic viral immunogen Mos3.3